Openbookopenbook
Equity
Rapid Therapeutic Science Lab inc(RTSL)
USD --+0.00%
Reward42Moderate
Risk73High
📊50%Data
Revenue down 97% YoY
RTSL
+0.0 · +0.00%
USD · PINK
Rapid Therapeutic Science Lab inc | Financial Services
Earnings Deterioration
Market Cap:113921
ℹ️
Reward Rating
42
Moderate
Bottom 10% (model universe)
50% data coverage
ℹ️
Risk Rating
73
High
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on RTSL to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Rapid Therapeutic Science Lab inc?

focuses on developing potential commercial opportunities which involve the rapid application of therapeutics using inhaler technology.

RTSL · Verdict

Moderate reward · high risk

RTSL's standout is volatility; cash flow and profitability weigh on the picture.

Based on 75% data coverage

RTSL · Verdict

What’s working & what to watch

Strengths 1

  • Volatility75/100

    Above average

Watchouts 3

  • Cash flow5/100

    Weak vs peers

  • Profitability10/100

    0% return on equity

  • Balance sheet14/100

    Current ratio 0.04

Model-based scoring. For information only — not financial advice.

What is Rapid Therapeutic Science Lab inc?

focuses on developing potential commercial opportunities which involve the rapid application of therapeutics using inhaler technology. The company was formerly known as Holly Brothers Pictures, Inc. The company is listed on the PINK in USA, operating in the Financial Services sector, with a market capitalisation of 113.92K, and a P/E ratio of 0.3x.

Financial Highlights

Investment Breakdown

📈 Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
💰 Profitability
Thin or inconsistent margins weigh on earnings quality.
⚠️ Risk
Performance tied to macro conditions — sensitive to interest rate cycles.
💸 Valuation
Valuation appears fair relative to current fundamentals.

OpenBook Logo Analysis

Reward: Moderate (42)

The scoring profile indicates limited reward potential at this time, with valuation and growth offering the most support. Risk indicators are high — this profile reflects meaningful downside exposure.

For informational purposes only. Not financial advice.

Company Information
SectorFinancial Services
Market Cap113.92K
P/E Ratio0.3
Dividend YieldN/A
52 Week High0.008
52 Week Low0.001
Last AnnualDecember
IPO DateN/A
IncorporatedUSA
Shares Outstanding19M
No. of Employees3
IndustryShell Companies
ExchangePINK
Beta-15.084
CurrencyUSD
Websitewww.rtslco.com
openbook

Stock research for everyday UK investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.